Sunday, July 6, 2025
  • Home
  • About us
  • Privacy policy
  • Advertise with us
  • Contact us
Fii News Logo
No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
Newsletter
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
Fiinews
No Result
View All Result
Home Exports

Aragen-Serum collaborates on HIV program

Fiinews by Fiinews
January 9, 2020
in Exports, Health, Imports, Manufacturing
Reading Time: 2 mins read
A A
0
Ind Ra
0
SHARES
10
VIEWS
LinkedinShare on Twitter

0:00

Accelerating Life Sciences R&D

 

GVK Bio/Aragen

 

California-based Aragen Bioscience and Serum Institute of India Pvt Ltd are collaborating for the development of multiple stable cell lines to support Serum’s HIV program.

The Serum and Aragen partnership is committed to ‘Accelerating Life Sciences R&D’ with the goal of developing affordable monoclonal antibodies that improve the quality of human life, said the two companies in a release on 8 Jan 2020.

Aragen will leverage its expertise with their RapTr™ platform utilizing proprietary vectors and CHO DG44 host cells to develop the cell lines.

Combined with the analytics platform, Aragen is set to provide Serum with high expressing cell lines enabling Serum to quickly move their program forward into Manufacturing.

With a proven track record of more than 50 years in developing affordable medicines, Serum will focus its efforts on advancing these novel molecules into impactful vaccines or therapies that treat and prevent diseases world-wide.

“We are delighted to partner with the global leader in Vaccines,” said Manni Kantipudi, Chairman, Aragen, & Chief Executive Officer, GVK BIO.

“The Aragen team is recognized globally for its ability to clone and express challenging proteins. Through this collaboration with Serum, we expect to build on this expertise to develop and deliver affordable biologicals.”

“SIIPL is very pleased to join hands with Aragen. SIIPL is already in collaboration with IAVI and Scripps Research for discovery of novel monoclonal antibodies against HIV,” said Adar Poonawalla, CEO, SIIPL of Hyderabad.

“With our manufacturing capabilities and this collaboration with Aragen to develop stable cell lines, SIIPL will be able to provide cost effective monoclonal antibodies against HIV for the developing and developed world,” he said.

GVK BIO, a leading Contract Research & Development Organization servicing the global Life-sciences industry, is headquartered in Hyderabad, India with operations in five sites including Aragen Bioscience in California.

Serum was founded in 1966 by Dr. Cyrus Poonawalla with a mission of manufacturing life-saving immuno-biologics. Serum is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses). fiinews.com

ShareTweetShare

Related Posts

SOPA
Exports

Export: India to ship non-GMO soybean to EU

by Fiinews
July 6, 2025
0
16

Global demand for deforestation-free non-GMO soy rises Indian non-GMO soy is a natural fit for EU buyers seeking sustainable and...

FICCI
Manufacturing

Manufacturing: Framework on Drones by Sep-Oct

by Fiinews
July 6, 2025
0
15

Lt Gen Singh urged industry to invest more on component level R&D Lt Gen Rahul R Singh, Deputy Chief of...

Toy Biz International2

Export: India supplies toys to 153 countries

July 6, 2025
19
Air Liquide

Manufacturing: Air Liquide builds ASU-CFS

July 5, 2025
13
NITI Aayog

Manufacturing: India’s chemical sector faces challenges

July 5, 2025
21
Ministry of Textile

Export: Govt to facilitate easy trade environment

July 2, 2025
15
SBI YONO

POPULAR NEWS

  • Cristina Dnv

    Projects: Indian yards set to build green ships, says DNV expert

    0 shares
    Share 0 Tweet 0
  • Market: Indian-origin UGF scales heritage consumer brands globally

    0 shares
    Share 0 Tweet 0
  • Technologies: Royal Diamond sponsors aerspace Industries’ drones in UAE

    0 shares
    Share 0 Tweet 0
  • Investments: Foreign investors see India as long-term destination for fund placings

    0 shares
    Share 0 Tweet 0
  • Markets: Blue Dart maintains positive outlook on India

    0 shares
    Share 0 Tweet 0

Fiinews.com features through news articles on business opportunities in the Indian market for the benefits of foreigners. It is also a platform for international businesses to showcase through elaborate articles on their products & services to the Indian consumers and corporations exploiting industrialisation of the country.

7Clicks Media is a Singapore based Media & PR company offering over 100,000
impressions via our targeted communication strategy.

It is led by editor-in-chief Gurdip Singh who has worked over 45 years reporting on
Asian businesses.

Recent News

  • Export: India to ship non-GMO soybean to EU
  • Tender: Take care of new urban development
  • Manufacturing: Framework on Drones by Sep-Oct
  • Project: Joint maritime professionals launched
  • Market: Daimler bullish on construction sector

Pages

  • About US
  • ADVERTISE ON FIINEWS.COM
  • CONTACT US
  • EVENTS
  • FII-NEWS.COM PDF ARCHIVE
  • Home
  • News
  • PRIVACY POLICY

Subscribe to Newsletter

  • About
  • Advertise
  • Careers
  • Contact us

© 2024 FIINEWS - Design and developed by 7clicksmedia.

No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports

© 2024 FIINEWS - Design and developed by 7clicksmedia.